Argatroban

A direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Argatroban, a direct thrombin inhibitor derived from arginine, is an effective anticoagulant indicated for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). Argatroban has been used as an alternative anticoagulant in patients with HIT in various clinical conditions including interventional cardiovascular procedures that require anticoagulation. Satisfactory clinical outcomes with acceptable complications have been reported in these patients. Whether argatroban offers additional clinical advantage over conventional heparin therapy in patients without HIT remains unclear. Argatroban has been evaluated as an alternative anticoagulant to replace heparin in various clinical studies, especially in patients with coronary artery disease or cerebral vascular disease. To date, it remains unclear if argatroban is more effective than heparin, although the agent seems to cause less bleeding complications. This article reviews the pharmacology of argatroban and its clinical application beyond the management of HIT, with particular emphasis on interventional cardiology procedure, acute myocardial infarction, unstable angina pectoris, cerebral thrombosis or ischemic stroke, peripheral obstructive arterial disease, and extracorporeal circulation.

Original languageEnglish (US)
Pages (from-to)189-198
Number of pages10
JournalHeart Disease
Volume3
Issue number3
StatePublished - 2001

Fingerprint

Antithrombins
Thrombocytopenia
Heparin
Anticoagulants
Intracranial Thrombosis
Extracorporeal Circulation
Peripheral Arterial Disease
Unstable Angina
argatroban
Cardiology
Vascular Diseases
Arginine
Coronary Artery Disease
Thrombosis
Stroke
Myocardial Infarction
Pharmacology
Hemorrhage
Therapeutics

Keywords

  • Acute coronary syndrome
  • Anticoagulation
  • Antithrombin III
  • Argatroban
  • Cerebral thrombosis
  • Direct thrombin inhibitors
  • Extracorporeal circulation
  • HIT
  • Interventional cardiology procedure
  • Myocardial infarction
  • Thrombin
  • Thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Argatroban : A direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications. / Chen, Julie L.

In: Heart Disease, Vol. 3, No. 3, 2001, p. 189-198.

Research output: Contribution to journalArticle

@article{08e75dca24c541819b10192bb06d6086,
title = "Argatroban: A direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications",
abstract = "Argatroban, a direct thrombin inhibitor derived from arginine, is an effective anticoagulant indicated for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). Argatroban has been used as an alternative anticoagulant in patients with HIT in various clinical conditions including interventional cardiovascular procedures that require anticoagulation. Satisfactory clinical outcomes with acceptable complications have been reported in these patients. Whether argatroban offers additional clinical advantage over conventional heparin therapy in patients without HIT remains unclear. Argatroban has been evaluated as an alternative anticoagulant to replace heparin in various clinical studies, especially in patients with coronary artery disease or cerebral vascular disease. To date, it remains unclear if argatroban is more effective than heparin, although the agent seems to cause less bleeding complications. This article reviews the pharmacology of argatroban and its clinical application beyond the management of HIT, with particular emphasis on interventional cardiology procedure, acute myocardial infarction, unstable angina pectoris, cerebral thrombosis or ischemic stroke, peripheral obstructive arterial disease, and extracorporeal circulation.",
keywords = "Acute coronary syndrome, Anticoagulation, Antithrombin III, Argatroban, Cerebral thrombosis, Direct thrombin inhibitors, Extracorporeal circulation, HIT, Interventional cardiology procedure, Myocardial infarction, Thrombin, Thrombosis",
author = "Chen, {Julie L.}",
year = "2001",
language = "English (US)",
volume = "3",
pages = "189--198",
journal = "Heart Disease",
issn = "1521-737X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Argatroban

T2 - A direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications

AU - Chen, Julie L.

PY - 2001

Y1 - 2001

N2 - Argatroban, a direct thrombin inhibitor derived from arginine, is an effective anticoagulant indicated for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). Argatroban has been used as an alternative anticoagulant in patients with HIT in various clinical conditions including interventional cardiovascular procedures that require anticoagulation. Satisfactory clinical outcomes with acceptable complications have been reported in these patients. Whether argatroban offers additional clinical advantage over conventional heparin therapy in patients without HIT remains unclear. Argatroban has been evaluated as an alternative anticoagulant to replace heparin in various clinical studies, especially in patients with coronary artery disease or cerebral vascular disease. To date, it remains unclear if argatroban is more effective than heparin, although the agent seems to cause less bleeding complications. This article reviews the pharmacology of argatroban and its clinical application beyond the management of HIT, with particular emphasis on interventional cardiology procedure, acute myocardial infarction, unstable angina pectoris, cerebral thrombosis or ischemic stroke, peripheral obstructive arterial disease, and extracorporeal circulation.

AB - Argatroban, a direct thrombin inhibitor derived from arginine, is an effective anticoagulant indicated for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). Argatroban has been used as an alternative anticoagulant in patients with HIT in various clinical conditions including interventional cardiovascular procedures that require anticoagulation. Satisfactory clinical outcomes with acceptable complications have been reported in these patients. Whether argatroban offers additional clinical advantage over conventional heparin therapy in patients without HIT remains unclear. Argatroban has been evaluated as an alternative anticoagulant to replace heparin in various clinical studies, especially in patients with coronary artery disease or cerebral vascular disease. To date, it remains unclear if argatroban is more effective than heparin, although the agent seems to cause less bleeding complications. This article reviews the pharmacology of argatroban and its clinical application beyond the management of HIT, with particular emphasis on interventional cardiology procedure, acute myocardial infarction, unstable angina pectoris, cerebral thrombosis or ischemic stroke, peripheral obstructive arterial disease, and extracorporeal circulation.

KW - Acute coronary syndrome

KW - Anticoagulation

KW - Antithrombin III

KW - Argatroban

KW - Cerebral thrombosis

KW - Direct thrombin inhibitors

KW - Extracorporeal circulation

KW - HIT

KW - Interventional cardiology procedure

KW - Myocardial infarction

KW - Thrombin

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0035213637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035213637&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 189

EP - 198

JO - Heart Disease

JF - Heart Disease

SN - 1521-737X

IS - 3

ER -